Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Decreases By 48.1%

Posted by Kyle Jackson on Mar 4th, 2025

NeuroMetrix, Inc. (NASDAQ:NURO – Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,400 shares, a decline of 48.1% from the January 31st total of 2,700 shares. Based on an average trading volume of 20,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are sold short.

NeuroMetrix Stock Down 0.5 %

Shares of NeuroMetrix stock traded down $0.02 on Monday, hitting $4.36. 26,232 shares of the company traded hands, compared to its average volume of 16,458. The company has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.05. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The company has a market cap of $8.95 million, a PE ratio of -0.95 and a beta of 2.18.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of NeuroMetrix in a report on Monday, February 24th. They set a “sell” rating on the stock.

Check Out Our Latest Report on NURO

Hedge Funds Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix as of its most recent SEC filing. Institutional investors and hedge funds own 19.40% of the company’s stock.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.